ARMI - KN

Background:

Here at the Advanced Regenerative Medicine Institute, we train doctors to provide stem cell and platelet-rich plasma (PRP) therapies. They go on to treat patients for a variety of musculoskeletal issues as well as hair loss and the effects of aging on the skin. We also teach doctors and clinic owners how to market regenerative medicine services after training is complete.

The One Profile Option That Could Undermine Your Journal Entry Controls

The One Configuration that Could Undermine Your Journal Entry Controls

Oracle EBS Personal Profile Values Form

One of the things we are sure to mention in our PRP and stem cell training is the fact that health insurance plans do not cover the procedures. As such, patients are left to pay for treatment out of pocket. This is both good and bad.

An interesting July article from Finance Magnates explored the dual concepts of stem cell therapy and virtual medicine. Though the article treated the two separately, it got us to thinking about what it would be like to combine them to treat a person suffering from some sort of musculoskeletal injury or disease. A sports injury or osteoarthritis immediately come to mind.

The Advanced Regenerative Medicine Institute goes beyond mere procedural training to include additional training for doctors and clinics looking for ways to successfully market stem cell and platelet-rich plasma (PRP) therapies. They come to us to learn the mechanics of the procedures, but we also teach them how to introduce those procedures to their patients.

This article is long overdue, but still one I have been dreading to release.  I know the audit firms could come under significant additional scrutiny from regulators such as the PCAOB.  However, there are significant risks organizations are facing because of poorly designed controls and inadequate audit procedures.  We’re now more than 20 years post-Sarbanes-Oxley, and it is time to shine the light on areas that board members and investors would be appalled by if they understood this topic.  With this said, here is my article…

We have observed an interesting trend in regenerative medicine over last 12 months or so: despite plenty of bad press fueled by a small number of shady stem cell clinics, interest in stem cell therapies continues to grow among both clinicians and patients alike. We have seen it first-hand as a steady stream of doctors continue signing up to take our stem cell therapy training courses. So what’s driving the interest? Clinical trials.